BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAR-210 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAR-210\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06919965-11225@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:TAR-210: Phase 3 readout est. (NCT06919965)
DESCRIPTION:TAR-210\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy:
  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in
  Participants With High Risk Non-Muscle-Invasive Bladder Cancer\nEstimated
  primary completion: 6 April 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tar-210#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06919965
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319820-11225@assetmemo.bio
DTSTAMP:20261121T005600Z
DTSTART;VALUE=DATE:20280628
DTEND;VALUE=DATE:20280629
SUMMARY:TAR-210: Phase 3 readout est. (NCT06319820)
DESCRIPTION:TAR-210\, phase 3.\nStudy: A Study to Evaluate TAR-210 Versus S
 ingle Agent Intravesical Cancer Treatment in Participants With Bladder Can
 cer\nEstimated primary completion: 28 June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/tar-210#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06319820
URL:https://assetmemo.bio/drug/tar-210#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
